Immunocore
-
Milton Park companies secure over 7% of UK’s life sciences equity investment
New research commissioned by Milton Park reveals that £2.14 billion of equity investment was generated across 272 companies based in the science, technology and business community over the past decade.
-
G7 health summit highlights Oxfordshire’s thriving life sciences sector
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
-
Immunocore closes $75m Series C private financing round
Led by an existing investor, the funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma.